- Home
- AIRI vs CLRB Comparison
AIRI vs CLRB Comparison
Compare AIRI & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- CLRB
- Stock Information
- Founded
- AIRI 1979
- CLRB 2002
- Country
- AIRI United States
- CLRB United States
- Employees
- AIRI N/A
- CLRB N/A
- Industry
- AIRI Military/Government/Technical
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- AIRI Industrials
- CLRB Health Care
- Exchange
- AIRI Nasdaq
- CLRB Nasdaq
- Market Cap
- AIRI 12.4M
- CLRB 12.5M
- IPO Year
- AIRI N/A
- CLRB N/A
- Fundamental
- Price
- AIRI $3.50
- CLRB $0.26
- Analyst Decision
- AIRI
- CLRB Hold
- Analyst Count
- AIRI 0
- CLRB 2
- Target Price
- AIRI N/A
- CLRB N/A
- AVG Volume (30 Days)
- AIRI 25.2K
- CLRB 739.3K
- Earning Date
- AIRI 05-15-2025
- CLRB 05-13-2025
- Dividend Yield
- AIRI N/A
- CLRB N/A
- EPS Growth
- AIRI N/A
- CLRB N/A
- EPS
- AIRI N/A
- CLRB N/A
- Revenue
- AIRI $53,182,000.00
- CLRB N/A
- Revenue This Year
- AIRI $5.59
- CLRB N/A
- Revenue Next Year
- AIRI $5.00
- CLRB N/A
- P/E Ratio
- AIRI N/A
- CLRB N/A
- Revenue Growth
- AIRI 0.29
- CLRB N/A
- 52 Week Low
- AIRI $3.00
- CLRB $0.22
- 52 Week High
- AIRI $9.44
- CLRB $3.42
- Technical
- Relative Strength Index (RSI)
- AIRI 51.22
- CLRB 46.10
- Support Level
- AIRI $3.20
- CLRB $0.23
- Resistance Level
- AIRI $3.54
- CLRB $0.27
- Average True Range (ATR)
- AIRI 0.22
- CLRB 0.02
- MACD
- AIRI 0.01
- CLRB 0.00
- Stochastic Oscillator
- AIRI 52.50
- CLRB 62.50
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.